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Chronic kidney disease (CKD) is a major public health problem. Accumulating evidence
suggests that CKD aggravates renal hypoxia, and in turn, renal hypoxia accelerates
CKD progression. To eliminate this vicious cycle, hypoxia-related therapies, such
as hypoxia-inducible factor (HIF) activation (prolyl hydroxylase domain inhibition) or
NF-E2-related factor 2 activation, are currently under investigation. Clinical studies have
revealed heterogeneity in renal oxygenation; therefore, the detection of patients with
more hypoxic kidneys can be used to identify likely responders to hypoxia-oriented
therapies. In this review, we provide a detailed description of current hypoxia detection
methods. HIF degradation correlates with the intracellular oxygen concentration; thus,
methods that can detect intracellular oxygen tension changes are desirable. The use of
a microelectrode is a classical technique that is superior in quantitative performance;
however, its high invasiveness and the fact that it reflects the extracellular oxygen
tension are disadvantages. Pimonidazole protein adduct immunohistochemistry and
HIF activation detection reflect intracellular oxygen tension, but these techniques yield
qualitative data. Blood oxygen level-dependent magnetic resonance imaging has the
advantage of low invasiveness, high quantitative performance, and application in
clinical use, but its biggest disadvantage is that it measures only deoxyhemoglobin
concentrations. Phosphorescence lifetime measurement is a relatively novel in vivo
oxygen sensing technique that has the advantage of being quantitative; however, it
has several disadvantages, such as toxicity of the phosphorescent dye and the inability
to assess deeper tissues. Understanding the advantages and disadvantages of these
hypoxia detection methods will help researchers precisely assess renal hypoxia and
develop new therapeutics against renal hypoxia-associated CKD.
Keywords: chronic kidney disease, hypoxia, hypoxia-inducible factor, Nrf2, microelectrode, pimonidazole, BOLD-
MRI, phosphorescence
INTRODUCTION
Chronic kidney disease (CKD) remains a major public health problem in both developed and
developing countries despite enormous treatment efforts (Collins et al., 2015; Liyanage et al., 2015).
Many clinical conditions, such as diabetes mellitus, glomerulonephritis, hypertension, and genetic
disorders, are causative factors of CKD. However, once renal fibrosis, a major pathological hallmark
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of CKD, reaches a certain threshold, CKD progression becomes
irreversible and independent of the initial cause (Fine et al.,
2000; Nangaku, 2006). Thus, the final common pathways of
CKD progression have been extensively studied. Renal hypoxia
(i.e., decreased oxygen tension in the kidney), particularly in
the tubulointerstitium, is a candidate prognostic marker for
CKD progression (Nangaku, 2006; Mimura and Nangaku, 2010).
Increased hemoglobin concentrations, which ameliorate renal
hypoxia, are associated with a better renal prognosis in CKD
patients (Tsubakihara et al., 2012). In support of hypoxia as
a marker of poor renal function, sleep apnea syndrome and
chronic obstructive pulmonary disease have been identified as
risk factors for CKD (Iseki et al., 2008; Hanly and Ahmed, 2014;
Chen and Liao, 2016). Although these studies are observational
and no intervention studies with domiciliary oxygen therapy or
continuous positive air pressure ventilation have been conducted,
our results raise the possibility that conditions, such as SAS
and COPD result in intermittent or continuous hypoxemia
and increase the risk of CKD development via renal hypoxia
aggravation.
CELLULAR RESPONSE TO HYPOXIA
Oxygen is imperative for mitochondrial oxidative
phosphorylation, a process that produces sufficient ATP amounts
in metazoans. Thus, cellular response against insufficient oxygen
supply is precisely controlled. Transcriptional factors known as
hypoxia-inducible factors (HIFs) play a central role in the anti-
hypoxia defense system (Semenza, 2014). HIFs are composed of
two subunits: HIF-α, an oxygen-sensitive subunit, and HIF-β,
an oxygen-insensitive subunit. The cellular concentration of
HIF-α is strictly tuned by the oxygen tension. Prolyl hydroxylase
domain (PHD) proteins hydroxylate HIF-α using oxygen
molecules as substrates. Next, hydroxylated HIF-α recruits von
Hippel–Lindau tumor suppressor, which triggers ubiquitination
and proteasomal degradation (Figure 1). In this mechanism,
HIF-α hydroxylation is the rate-limiting step. Therefore,
the cellular concentration of HIF-α is dependent on oxygen
tension. Given that HIF-α hydroxylation occurs in the cytosol,
the intracellular oxygen tension is more important than the
extracellular oxygen tension, which is usually estimated by
measuring the intravascular oxygen tension.
Increases in cytoplasmic HIF-α concentrations due to
decreased intracellular oxygen tension or PHD pharmacological
inhibition lead to the formation of a heterodimer between HIF-α
and HIF-1β. The heterodimer translocates into the nucleus
and binds to the consensus enhancer via hypoxia-responsive
elements (HREs), which then upregulates downstream target
genes. The representative downstream genes include vascular
endothelial growth factor (VEGF), erythropoietin (EPO), glucose
transporter 1, and heme oxygenase 1, which protect the cell
from hypoxia by promoting neovascularization, erythropoiesis,
and glycolysis and by decreasing oxidative stress, respectively.
There are three isoforms of HIF-α: HIF-1α, HIF-2α, and HIF-3α.
In the kidney, HIF-1α is dominantly expressed in tubular cells,
whereas HIF-2α accumulates in interstitial and endothelial cells
(Rosenberger et al., 2002). The expression and function of HIF-
3α remains elusive. Full-length HIF-3αworks as a transcriptional
factor with HIF-1β; however, some of its splice variants work
as dominant negative forms against HIF-1α and HIF-2α (Duan,
2016).
RENAL HYPOXIA PATHOPHYSIOLOGY
The oxygen tension in the kidney is relatively lower in healthy
individuals, even though the kidneys receive approximately 20%
of the blood pumped out from the heart. One explanation
is the oxygen shunt between the arterial and venous vessels
that run parallel in the kidney, as proven by oxygen electrodes
(Schurek et al., 1990). Recently, it has been actively debated
whether an arteriovenous oxygen shunt affects renal oxygenation
based on results from a three-dimensional computational model.
To obtain a clear answer, the quantification of the geometry
of artery–vein pairs in the kidney may be needed as results
from the three-dimensional computational model vary with
the assumption of background vascular networks (Ngo et al.,
2014; Evans et al., 2015; Olgac and Kurtcuoglu, 2015). An
oxygen shunt supposedly affects renal oxygenation and is
likely accountable for the higher oxygen tension in renal
veins than in efferent arterioles (Welch et al., 2001) and for
the oxygen gradient in the kidney, i.e., the oxygen tension
decreases deeper in the renal surface. The oxygen tension in
the renal surface is approximately 50 mmHg, whereas the
tension in the renal medulla is approximately 30 mmHg, as
detected by microelectrodes (Friederich-Persson et al., 2013;
Ow et al., 2014; Nordquist et al., 2015). A lower oxygen
tension in normal kidneys has also been shown in a study
that visualized HIF activity in transgenic mice (Safran et al.,
2006). In these mice, the luciferase enzyme was fused to
the oxygen-dependent degradation domain of HIF-1α. Thus,
luciferase activity simulated HIF-α expression. Under normoxic
conditions, the kidneys were the only organ that expressed
sufficient luminescence that could be observed in the in vivo
system.
In addition to its innate low oxygen tension, the kidneys
suffer from severe hypoxia as CKD progresses. Renal hypoxia
pathophysiology in CKD includes a decrease in oxygen supply
and an increase in oxygen consumption. Loss of peritubular
capillaries (PTCs) (Kang et al., 2001b; Ohashi et al., 2002),
reduction in PTC flow (Matsumoto et al., 2004), and renal
anemia (Astor et al., 2002) account for insufficient oxygen
supply. Increases in oxygen demand in renal tubules have
been shown in a reduced renal mass model (Harris et al.,
1988; Nath and Paller, 1990), hypertensive model (Adler and
Huang, 2002), and diabetes mellitus model (Korner et al.,
1994), and this increase in the reduced renal mass model
is corrected by renin–angiotensin–aldosterone axis blockade
or HIF activation (Deng et al., 2009, 2010). These hypoxic
changes likely exacerbate renal tubular damage. Outer medullary
areas, including the S3 segment of the proximal tubules,
medullary thick ascending limbs, and medullary collecting ducts,
are considered to be most susceptible to hypoxia because
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FIGURE 1 | HIF-α regulation. In the presence of sufficient oxygen, HIF-α is hydroxylated by PHD. Hydroxylated HIF-α is recognized by vHL, which results in
proteasomal degradation. In hypoxic conditions or PHD inhibition, HIF-α accumulates in the cytosol and forms a heterodimer with HIF-β, the hypoxia-insensitive unit.
The heterodimer translocates to the nucleus and acts as a transcriptional factor that binds to HREs. Abbreviations: HIF, hypoxia-inducible factor; HREs,
hypoxia-responsive elements; PHD, prolyl hydroxylase domain; vHL, von Hippel–Lindau disease tumor suppressor.
histological changes are obvious in these segments of human
kidneys with ischemia (Heyman et al., 2010). Differences in
several features, including mitochondrial density and transport
activity, account for the susceptibility to hypoxic insults. The
medullary thick ascending limbs and medullary collecting ducts
become more susceptible to hypoxic insults with forced tubular
transport (Shanley et al., 1986; Brezis and Rosen, 1995; Epstein,
1997).
HYPOXIA-ORIENTED THERAPY AGAINST
CKD
Renal hypoxia accelerates CKD progression, and in turn,
CKD exacerbates renal hypoxia. Therefore, eliminating this
cycle is a promising strategy against CKD. One approach
is HIF activation via PHD inhibition. Cobalt chloride is a
classical PHD inhibitor, and it ameliorates CKD progression
in a model of STZ-induced type 1 diabetes and Thy-1
nephritis and a remnant kidney model (Tanaka et al., 2005a,b;
Nordquist et al., 2015). However, this treatment cannot be
used in CKD patients because of severe adverse effects. PHD
inhibitors that specifically inhibit HIF-α hydroxylation have
recently been synthesized. These compounds are currently
in clinical trials for renal anemia because the EPO gene is
markedly upregulated by HIF-α stabilization (Fraisl et al., 2009;
Maxwell and Eckardt, 2016), and several drugs show positive
outcomes in clinical trials in non-dialysis CKD patients and
dialysis patients (Besarab et al., 2016; Brigandi et al., 2016;
Holdstock et al., 2016; Pergola et al., 2016; Provenzano et al.,
2016). These drugs are expected to have protective effects
against CKD.
OXIDATIVE STRESS-ORIENTED THERAPY
AGAINST CKD
Another treatment approach is the enhancement of the anti-
oxidant response because hypoxia is closely related to increased
oxidative stress. One relevant transcriptional factor for this
approach is NF-E2 related factor 2 (Nrf2). Nrf2 is degraded via
recognition by Kelch-like ECH-associated protein 1 (Keap1) in
the cytosol under normal conditions. When certain chemical
stresses, such as oxidative stress, are induced, Nrf2 escapes
degradation, translocates into the nucleus, binds to anti-oxidant
responsive elements (AREs), and upregulates downstream genes
(Bryan et al., 2013; Figure 2). Nrf2–ARE axis activation induces
strong anti-oxidative effects; therefore, the pharmacological
activation of the Nrf2–ARE pathway is a promising target for
various diseases, including kidney diseases. Bardoxolone methyl,
an Nrf2 activator via Keap1 inhibition, increases eGFR in
CKD patients with diabetes mellitus; however, the change in
eGFR is not considered primary or secondary outcomes, and
hypertension and an increased urinary albumin-to-creatinine
ratio was seen in the bardoxolone group (Pergola et al., 2011; de
Zeeuw et al., 2013). However, a high frequency of cardiovascular
events in the bardoxolone methyl group led to the termination of
the phase III trial (de Zeeuw et al., 2013). A subsequent analysis
revealed that most of these patients suffered from excessive
fluid retention at the early stage. Considering that these clinical
signs can be predicted under close follow-up of the patients and
that diabetic kidney disease is major cause of end-stage renal
disease, the potential benefit of this drug was reconsidered and
a new phase II trial that excludes patients with a high risk of
cardiovascular disease is ongoing in Japan.
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FIGURE 2 | Nrf2 regulation. Under normal conditions, Nrf2 is recognized by KEAP1, which triggers its proteasomal degradation. In contrast, under stressful
conditions, such as increased oxidative stress, Nrf2 recognition by KEAP1 is disturbed, and Nrf2 accumulates in the cytosol and acts as a transcriptional factor via
ARE binding. Abbreviations: ARE, anti-oxidant responsive element; KEAP1, Kelch-like ECH-associated protein 1; Nrf2, NF-E2 related factor 2.
These hypoxia-targeting pharmaceutical therapies are
promising. Theoretically, these therapies are effective only on
patients whose kidneys are truly hypoxic. The renal oxygen state
widely varies in CKD patients (Michaely et al., 2012). Thus, it
is important to identify patients whose kidneys are sufficiently
hypoxic, i.e., more responsive to hypoxia-oriented therapies.
However, the currently available hypoxia detection methods
have serious disadvantages. Thus, there is a compelling need for
a better understanding of hypoxia detection methods.
GENERAL PRINCIPLES OF OXYGEN
TENSION ASSESSMENT
The most important function of oxygen molecules is their action
as an oxidant. In addition, oxygen can bind to hemoglobin
to increase its solubility in blood. A lower oxygen tension
results in HIF–HRE axis activation. Thus, we consider that
methods to measure the oxygen tension can be divided into
four groups: (i) assessment of the oxidative power of oxygen
molecules (Clark, 1956; Arteel et al., 1995), (ii) measurement
of the oxyhemoglobin/total hemoglobin ratio (Prasad et al.,
1996), (iii) detection of HIF activity (Safran et al., 2006),
and (iv) direct measurement of oxygen molecules by the
assessment of fluorescence or phosphorescence quenching rate
(Rumsey et al., 1988; Mik et al., 2006). Although these
four methods unequivocally depend on the oxygen tension,
there are some confounding factors in their interpretation.
For example, when the oxidative power of oxygen molecules
is measured, other oxidants or reductants can influence the
result. Notably, oxidative stress levels increase in CKD patients
(Himmelfarb et al., 2002). Although the oxyhemoglobin/total
hemoglobin ratio is clinically used to determine a patient’s
general oxygenation state, this value can be affected by the
partial pressures of oxygen and carbon dioxide, changes in pH,
and other micro-environmental changes (Bohr effect). Blood
oxygen level-dependent magnetic resonance imaging (BOLD-
MRI) employs hemoglobin as an oxygen sensor; however, this
method only measures the deoxyhemoglobin concentration and
not the deoxyhemoglobin/total hemoglobin ratio. Thus, this
method is influenced by the hemoglobin concentration, which
cannot be precisely measured in small veins (Prasad et al., 1996).
Renal anemia and acid–base disorders frequently occur in CKD
patients, which may explain why the use of renal BOLD-MRI in
CKD patients remains controversial (Inoue et al., 2011; Michaely
et al., 2012; Pruijm et al., 2014). HIF activation may be influenced
by factors other than oxygen molecules, such as erythropoietin
and indoxyl sulfate (Chiang et al., 2011). Indoxyl sulfate, a
representative uremic toxin, suppresses EPO gene transcription
in hypoxic HepG2 cells in an HIF-dependent manner, and the
oral administration of indole, a precursor of indoxyl sulfate,
decreases the serum erythropoietin concentration in rats.
Another important consideration is whether the method
employed reflects the intracellular or extracellular oxygen
tension. As previously noted, the HIF-mediated cellular response
against hypoxia is regulated by the hydroxylation of HIF-α,
which uses oxygen as a substrate. Thus, the intracellular oxygen
tension is important. For example, anemia can cause dissociation
between the intracellular and extracellular oxygen tensions
because anemia does not change the partial pressure of oxygen,
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but rather changes the total oxygen amount in arterial blood
(i.e., decrease in hemoglobin concentration). This condition
should not be overlooked because renal anemia development is
associated with renal hypoxia in CKD patients.
Another important aspect to consider is the generation of
quantitative or qualitative data. Microelectrodes, BOLD-MRI,
pimonidazole protein adduct immunohistochemistry, and HIF
activation detection are frequently used as hypoxia detection
methods (Heyman et al., 2008). Phosphorescence lifetime
measurement is a relatively novel intravital oxygen sensing
technique; thus, we have included this technique in our review
(Parpaleix et al., 2013; Spencer et al., 2014; Hirakawa et al., 2015).
The characteristics of these methods are summarized in Table 1.
For clinical applications, BOLD-MRI is the only appropriate
method. For animal experiments, microelectrodes are a gold
standard for oxygen tension measurement, although the specific
measurement site is unclear. Pimonidazole staining and HIF
activation detection can be used for paraffin sections and has
the advantage of spatial resolution. Phosphorescence lifetime
measurement is a highly sensitive method, but it requires special
instrumentation.
Comparison of results obtained via different methods is
attractive, and there is a report that compared pO2 measured by
a microelectrode with that measured by a fluorescence needle
probe in the kidney and which mentions that there is a slight
difference in outcomes between these two methods (O’Connor
et al., 2006). However, this comparison cannot determine which
of the two methods is reliable; the calibration method of each
method differs, and the measurement site is not always the
same. Therefore, the comparison of pO2 obtained via different
techniques needs to be interpreted with that consideration in
mind.
HYPOXIA DETECTION METHODS
Microelectrodes
The use of microelectrodes is a classical technique and the gold
standard for determining the oxygen tension in living cells and
animals. The principle of this technique is based on oxidation–
reduction reactions. The reaction for a silver electrode is shown
below:
4Ag+ 4Cl− → 4AgCl+ 4e− · · · (1)
4H+ + 4e− +O2 → 2H2O · ·· (2)
This reaction contains an oxygen molecule as a reactant in
Equation 2; thus, the electric current is dependent on the
oxygen concentration, assuming that the voltage is constant.
This method is widely used to determine renal oxygenation
as well as other visceral organ oxygenation, such as the liver.
The kidney has a natural oxygen gradient; therefore, data
obtained from amicroelectrode is dependent on depth. Typically,
representative oxygen tensions in the renal cortex and medulla
are 50 and 30 mmHg, respectively. This ability to distinguish
between the renal cortex and the medulla is an advantage of
the microelectrode; however, technical proficiency is required to
accurately measure medullary oxygen tension. This technique
has two major disadvantages, in addition to its non-applicability
in humans. First, this method is highly invasive. The technique
requires renal capsule removal and needle insertion into the renal
tissue, which results in microbleeding. This method intrinsically
hinders repeat measurements within an individual. The second
disadvantage is that microelectrodes measure the partial pressure
of oxygen from both microcirculation and microbleeding based
on the fact that a microelectrode is slightly pulled after insertion
to prevent compression. Despite these disadvantages, the use of
microelectrodes remains the gold standard for determining tissue
oxygen tension because of its superior quantitative performance.
To overcome the disadvantages of this established method,
novel modifications have been developed. The first involves the
use of telemetry (Koeners et al., 2013; Emans et al., 2016).
For oxygen tension telemetry, carbon paste electrodes are used
to avoid surface poisoning (Bolger et al., 2011). Once the
electrodes are implanted, renal oxygenation can be monitored
for 2 weeks without anesthesia. This technique resolves
the two major disadvantages inherent to the conventional
microelectrode method, including the continuous measurement
within an individual and the avoidance of acute effects from
general anesthesia. Another approach is urinary oxygen tension
measurement (Evans et al., 2014). Urinary oxygen tension reflects
renalmedullary oxygen tension and is useful formonitoring renal
oxygenation in critically ill patients (Kainuma et al., 1996; Morelli
et al., 2003). This technique does not require intervention other
than the insertion of electrode-equipped bladder catheters; thus,
it has the advantage of being easily applied in clinical settings.
One disadvantage is the general lack of proof of this in smaller
animals. However, a recent study in rabbits reported the ability of
urinary oxygen tension measurements to reflect renal medullary
oxygen tension (Sgouralis et al., 2016).
Nitroimidazole Probes
Pimonidazole is a nitroimidazole. Nitroimidazoles are hypoxic
markers that were initially used to detect hypoxic tumors, which
are frequently resistant to radiotherapy. Pimonidazole was used
to detect tissue hypoxia in a physiological range (Arteel et al.,
1995). Under normoxic conditions, pimonidazole is oxidized by
oxygen molecule, whereas pimonidazole is reductively activated
under hypoxic conditions. Reduced pimonidazole binds to
intracellular thiol-containing proteins. Pimonidazole protein
adducts are only detected in hypoxic cells after systemic
administration. The detection of pimonidazole protein adducts
is typically achieved by immunohistochemistry. Thus, this
technique requires the systemic administration of pimonidazole
and the preparation of paraffin-embedded sections or frozen
sections, which prohibits its use in living animals. Another
disadvantage is that this technique reflects the redox state;
thus, a redox imbalance independent of the oxygen tension
can influence the result. In the kidneys, pimonidazole-positive
areas are naturally observed in the medulla and corticomedullar
junction (Manotham et al., 2004; Fong et al., 2016), which
supports the idea that these areas are more hypoxic than the
superficial cortex. In CKD models, the pimonidazole-positive
area expands (Manotham et al., 2004; Tanaka et al., 2006). This
technique can only detect areas with oxygen tensions lower than
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TABLE 1 | Comparison of hypoxia detection methods.
Method What is measured? Intracellular/extracellular Qualitative/quantitative Clinical applicability
Pimonidazole staining Oxidative power of O2 Intracellular Qualitative PET probe only
Microelectrode Oxidative power of O2 Extracellular Quantitative No
Detection of the activated HIF–HRE axis Activation of the HIF–HRE axis Intracellular Qualitative No
BOLD-MRI Deoxyhemoglobin concentration Extracellular Quantitative Yes
Phosphorescence lifetime measurement Quenching by an oxygen molecule Depends on dyes Quantitative No
BOLD-MRI, blood oxygen level-dependent magnetic resonance imaging; HIF, hypoxia-inducible factor; HRE, hypoxia-responsive element.
a certain threshold (approximately below 10 mmHg); thus, it is
neither quantitative nor indicative of the oxygen tension.
To overcome the disadvantage of paraffin-embedded
sections, several positron emission tomography (PET) tracers
with nitroimidazoles have been studied. For example, 18F-
fluoroazomycin arabinoside (18F-FAZA) (Piert et al., 2005) was
found to accumulate in hypoxic tumors. This probe can be
administered in clinical settings, and several papers have proved
that it is useful for prognostic prediction in non-small-cell lung
cancer (Saga et al., 2015; Kinoshita et al., 2016). It remains
unclear if this method can successfully detect renal hypoxia in
healthy individuals or CKD patients. The difficulty in detecting
renal hypoxia is based on the fact that the oxygen tension of
non-tumorous organs, including the kidney, is likely to be much
milder than that of tumor tissues, even in pathological conditions
(Handley et al., 2011). Pimonidazole binds to intracellular thiols
at oxygen tensions below 10 mmHg, which is frequently lower
than the tensions found in non-tumorous tissues. Another
disadvantage is that 18F-FAZA is physiologically distributed
to even normal kidneys and is excreted from the kidney like
other PET tracers (Koh et al., 1992). In PET imaging, there
is limited resolution with which to distinguish PET probes in
the urinary space and intracellular PET probes. However, PET
tracing using nitroimidazoles is potentially preferred because this
technique is less invasive and suitable for use in CKD patients.
Furthermore, this probe reflects the intracellular rather than the
extracellular oxygen tension. The optimization of the oxygen
tension threshold and biokinetics of PET tracers may overcome
the disadvantages listed above and result in new information on
renal hypoxia in CKD patients.
HIF Activation Detection
The cellular response against hypoxia is mainly regulated by
HIF; therefore, HIF activation can be used as evidence on
tissue hypoxia. One detection method assesses HRE-downstream
genes or proteins in tissues. The advantage of this method
is that several HIF target proteins are hypoxia markers and
affect CKD progression. An example of one of these targets is
VEGF. The transcription of the VEGF gene is strongly enhanced
under hypoxic conditions. Exogenous VEGF administration
ameliorates renal fibrosis in a remnant kidney model, whereas
sunitinib administration, a VEGF receptor inhibitor, worsens
renal injury in this model (Kang et al., 2001a; Machado et al.,
2012), although sunitinib also blocks the platelet-derived growth
factor receptor. The expression of HIF target genes can be
affected by other transcriptional factors and thus is not always
affected by the oxygen tension alone. The protein level of VEGF
can remain unchanged in some CKD models despite renal
hypoxia (Futatsugi et al., 2016).
Classical techniques, such as reverse transcription PCR
and immunohistochemistry, require tissue sample preparation.
Another method is the in vivo imaging of HIF activity using
luciferase. Our group established hypoxia-sensing transgenic
rats, in which the luciferase gene was controlled by tandem
repeats of HREs located in the 5′ UTR of the VEGF gene
(Tanaka et al., 2004). A similar approach was employed by
Safran et al. who established a hypoxia-sensing mouse strain
that expressed firefly luciferase fused to the HIF-1α protein
(Safran et al., 2006). These animals emit luminescence after the
administration of a systemic chemiluminescent substrate, and
the luminescence can be measured from outside the body. This
strain was used to detect a decrease in HIF-α hydroxylation
induced by hypoxemia and pharmacological PHD inhibition.
The advantage of this technique is the lack of autoluminescence
in the body, whereas a disadvantage is the reabsorption of
luminescence. The kidney contains a significant amount of
blood; thus, it can absorb light at an optical wavelength. It
is unclear if luminescence from the kidney truly reflects total
renal luciferase activity or only superficial activity. Kuchimaru
et al. may have overcome this disadvantage (Kuchimaru et al.,
2016). They succeeded in synthesizing a novel luminescent
substrate whose wavelength was considerably longer (λmax =
677 nm) than classical luciferins. Owing to its near-infrared
wavelength, this substrate can be used to observe deeper
tissue and will definitely aid in the intravital imaging of HIF
activity.
MRI-Based Assessment
BOLD-MRI is a useful tool to evaluate renal oxygenation. Here,
the spin–spin relaxation rate R2∗ is measured, which reflects the
deoxyhemoglobin concentration in veins (Prasad et al., 1996).
To use this technique for tissue oxygenation approximation,
we must speculate three proportional relationships: the
deoxyhemoglobin concentration and deoxyhemoglobin/total
hemoglobin ratio, deoxyhemoglobin/total hemoglobin ratio
and partial pressure of oxygen in veins, and partial pressure
of oxygen in veins and tissue oxygen level. These three
proportional relationships are confounded by the hemoglobin
concentration in veins, change in the oxygen affinity of
hemoglobin, and intracellular/extracellular oxygen tension
Frontiers in Physiology | www.frontiersin.org 6 February 2017 | Volume 8 | Article 99
Hirakawa et al. Hypoxia in Chronic Kidney Disease
dissociation, respectively. Renal anemia and systemic acid–
base disorders frequently occur in CKD patients, which may
change the oxygen affinity of hemoglobin. The existence of
an oxygen shunt in renal arterial and venous vessels suggests
that the oxygenation of renal venous vessels is independent
of tissue oxygenation. These disadvantages must be taken
into account when interpreting data from BOLD-MRI of the
kidney.
Despite these disadvantages, BOLD-MRI is a promising
method because it is a non-invasive technique, particularly
when applied in humans. A previous report has shown that
the renal R2∗ value correlated with eGFR in CKD patients
without diabetes (Inoue et al., 2011), whereas another report
did not find this correlation in CKD patients (Michaely et al.,
2012). The discrepancy between these two reports may be due to
differences in patient backgrounds. Another report has indicated
there are several factors other than the oxygen tension, such as
blood glucose and uric acid levels, that influence the result of
BOLD-MRI, whether directly or indirectly (Pruijm et al., 2014).
It is debatable whether BOLD-MRI can properly address the
heterogeneity of CKD patients.
BOLD-MRI, an R2∗-based technique, employs hemoglobin
as an oxygen sensor. However, another MRI-based technique
that directly measures oxygen molecules has been recently
reported (O’Connor et al., 2009; Winter et al., 2011). In
this technique, the relaxation rate of the T1 signal (R1) is
measured, which is related to the oxygen molecule itself.
One report has suggested that R1 in lipids changes with
the oxygen tension in mice tumors, whereas another report
has shown that the R1-based technique is less sensitive in
detecting renal hypoxia in hypoxemia than the R2∗-based
technique (Jordan et al., 2013; Ganesh et al., 2016). Together
with the low invasiveness of MRI-based techniques and the
limitation of BOLD-MRI, R1-based measurement is a potentially
viable method because it directly determines the oxygen
tension.
Phosphorescence
Phosphorescence is a type of light emitted from a molecule
in the triplet excited state. Molecules in this state can
lose their energy by being hit by oxygen molecules.
Phosphorescence intensity and phosphorescence lifetime
depend on the oxygen concentration (Rumsey et al., 1988).
Thus, this technique can directly measure the oxygen
tension. Substances that emit phosphorescence are limited,
and exogenous phosphorescence dyes are used to measure
phosphorescence. Notably, the phosphorescence lifetime is far
longer than the fluorescence lifetime. Both phosphorescence
intensity and phosphorescence lifetime can be quantitatively
measured. However, phosphorescence dye concentrations
in the target organ are required to determine the oxygen
tension in vivo using the phosphorescence intensity. Therefore,
phosphorescence lifetime measurements are frequently used
to determine the oxygen tension in vivo (Mik et al., 2008;
Parpaleix et al., 2013; Spencer et al., 2014; Hirakawa et al.,
2015). The phosphorescence lifetime does not depend on
dye concentration as long as it sufficiently accumulates. In
phosphorescence lifetime measurements, the Stern–Volmer
equation is used:
[O2] =
1
kq
(
1
τ
−
1
τ0
)
· ·· (3)
where kq is the rate constant, τ is the phosphorescence
lifetime at the oxygen concentration of [O2], and τ0 is the
phosphorescence lifetime in an anoxic condition (Vanderkooi
et al., 1987). These two constants, kq and τ0, depend on the
phosphorescence dye and circumstantial microcondition, such
as solvent. Thus, the determination of these parameters is
problematic.
The oxygen dependence of the phosphorescence lifetime was
established in the 1980s. It is utilized with fluorescence needle
probes, which contain an oxygen-sensitive fluorescence dye, such
as protoporphyrin IX (PpIX) described below, which has similar
characteristics against oxygen. Several studies have employed
this fluorescence needle probe because of its high sensitivity to
the oxygen tension (O’Connor et al., 2006; dos Santos et al.,
2007). However, this method cannot overcome the two major
disadvantages of microelectrodes: unclear measurement site and
high invasiveness. Thus, another way to apply phosphorescence
lifetime measurement to in vivo O2 measurement is warranted,
and currently, the administration of phosphorescence dyes that
are distributed in a certain tissue or cell is frequently used.
One research milestone was the report by Spencer et al. (2014).
They employed a water-soluble phosphorescence dye, PtP-
C343, to measure the oxygen tension in arterioles penetrating
cortical bones and showed that the oxygen tension decreased
when the arteriole entered the medullary canal in mice. This
research directly proved the lower oxygen tension in the
bone marrow, which was hypothesized based on the unique
vasculature system in the marrow and pimonidazole protein
adduct immunohistochemistry (Suda et al., 2011; Nombela-
Arrieta et al., 2013).
Powerful research on the kidney was published by Mik
et al. (2008). They used Oxyphor G2 as a water-soluble
phosphorescence dye and proved that oxygen tension in renal
vein was decreased after endotoxin shock in rats. This work
clarified where the oxygen tension should be measured (i.e., in
renal veins). The phosphorescence dye is excited only in blood
in renal vein. In this study, there is no phosphorescence signal
from arterial blood, capillary blood, or interstitial fluid, which is
problematic in the study of solid organs.
The aforementioned phosphorescence dyes are distributed
in the extracellular fluid, mainly in the blood; thus, these
dyes cannot directly determine the intracellular oxygen tension.
Our group recently reported a novel technique for measuring
the intracellular oxygen tension using BTPDM1, a cationic
lipophilic phosphorescence dye (Yoshihara et al., 2015). In
the kidney, this dye is found only inside tubular cells. Thus,
phosphorescence lifetime imaging reflects only the intracellular
oxygen tension in tubules. Using this method, phosphorescence
lifetime measurement revealed renal hypoxia in CKD, and
the phosphorescence lifetime was successfully converted to the
partial pressure of oxygen using the calibration curve obtained
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from a cultured tubular cell line. One disadvantage of this
technique is dye toxicity when applied in human beings because
BTPDM1 contains iridium, a heavy metal. Another dye that
may overcome this disadvantage is PpIX (Mik et al., 2006).
PpIX is a precursor of heme and is unique in that it can
emit delayed fluorescence. This delayed fluorescence is similar
to phosphorescence in terms of oxygen sensitivity, i.e., its
phosphorescence lifetime depends on the oxygen tension. PpIX
localizes to the mitochondria, and its physiological concentration
is so low that it cannot be used as an endogenous oxygen sensor.
However, when a large amount of 5-aminolevulinic acid (5-
ALA), a PpIX precursor, is administered, the cellular synthesis of
PpIX sufficiently increases to allow its use as an oxygen sensor via
delayed fluorescence lifetime measurements. Using this method,
the topical application of 5-ALA enables PpIX accumulation in
the skin of healthy human volunteers and the oxygen tension
estimate in human skin (Harms et al., 2013). Thus, this technique
can be applied to abdominal organs, such as the liver (Bodmer
et al., 2012). These phosphorescence or delayed fluorescence
lifetime measurement techniques have the advantage of direct
oxygen measurements and a superior quantitative performance.
In contrast, these techniques cannot be used for assessing the
deeper portion of the kidney, such as the outer medullary region,
because phosphorescence is absorbed in tissues, particularly by
hemoglobin.
CONCLUSION AND FUTURE
PERSPECTIVES
In this review, we addressed the pathophysiological importance
of renal hypoxia with a focus on hypoxia detection. Although
oxygen tension determination has been studied for a long
time, recent advances have made it possible to achieve
continuous measurements, non-invasive oxygen assessments,
and intracellular oxygen assessments. All these methods have
their advantages and disadvantages; therefore, a comprehensive
understanding and proper selection of the available methods
are required to assess renal hypoxia and identify the final
common pathway in individual hypoxia patients. Thus, a
sufficient understanding of oxygen detection techniques will
help researchers develop new drugs against CKD and renal
hypoxia.
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